Total Payments
$28,821
2024 Payments
$2,169
Companies
28
Transactions
389
Medicare Patients
3,125
Medicare Billing
$520,324
Payment Breakdown by Category
Research$19,870 (68.9%)
Food & Beverage$7,170 (24.9%)
Travel$1,750 (6.1%)
Education$31.50 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $19,870 | 11 | 68.9% |
| Food and Beverage | $7,170 | 369 | 24.9% |
| Travel and Lodging | $1,750 | 8 | 6.1% |
| Education | $31.50 | 1 | 0.1% |
Payments by Type
Research
$19,870
11 transactions
General
$8,951
378 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $19,604 | 7 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $1,165 | 3 | $0 (2024) |
| Eisai Inc. | $1,152 | 16 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $1,098 | 52 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $815.09 | 44 | $0 (2024) |
| Allergan, Inc. | $619.02 | 65 | $0 (2020) |
| Lundbeck LLC | $561.23 | 26 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $503.90 | 3 | $0 (2017) |
| Otsuka America Pharmaceutical, Inc. | $484.91 | 30 | $0 (2024) |
| ACADIA Pharmaceuticals Inc | $479.22 | 29 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,169 | 50 | E.R. Squibb & Sons, L.L.C. ($1,165) |
| 2023 | $8,633 | 36 | Eli Lilly and Company ($7,955) |
| 2022 | $7,944 | 29 | Eli Lilly and Company ($7,429) |
| 2021 | $1,497 | 26 | Eli Lilly and Company ($1,009) |
| 2020 | $285.29 | 15 | Teva Pharmaceuticals USA, Inc. ($95.03) |
| 2019 | $1,197 | 80 | Teva Pharmaceuticals USA, Inc. ($229.12) |
| 2018 | $1,646 | 84 | Teva Pharmaceuticals USA, Inc. ($398.82) |
| 2017 | $5,449 | 69 | Eli Lilly and Company ($3,210) |
All Payment Transactions
389 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $29.20 | General |
| Category: Central Nervous System | ||||||
| 12/05/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $27.98 | General |
| Category: Neurology | ||||||
| 11/12/2024 | Lilly USA, LLC | AMYVID (Drug), KISUNLA | Food and Beverage | In-kind items and services | $24.70 | General |
| Category: Neuroscience | ||||||
| 11/06/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $25.93 | General |
| Category: PSYCHIATRY | ||||||
| 11/05/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $21.17 | General |
| Category: PSYCHIATRY | ||||||
| 10/31/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $18.42 | General |
| Category: NEUROSCIENCE | ||||||
| 10/29/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $14.37 | General |
| Category: Central Nervous System | ||||||
| 10/28/2024 | Biogen, Inc. | SKYCLARYS (Drug) | Food and Beverage | In-kind items and services | $27.77 | General |
| Category: Neurology | ||||||
| 10/23/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $19.09 | General |
| Category: PSYCHIATRY | ||||||
| 10/22/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $20.31 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 10/15/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $25.82 | General |
| Category: NEUROSCIENCE | ||||||
| 10/03/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $18.46 | General |
| Category: Neuroscience | ||||||
| 09/24/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $19.50 | General |
| Category: PSYCHIATRY | ||||||
| 09/23/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $21.02 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 09/17/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $12.64 | General |
| Category: Central Nervous System | ||||||
| 09/03/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $29.09 | General |
| Category: PSYCHIATRY | ||||||
| 08/20/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $17.41 | General |
| Category: NEUROSCIENCE | ||||||
| 08/15/2024 | Lilly USA, LLC | AMYVID (Drug), KISUNLA | Food and Beverage | In-kind items and services | $18.58 | General |
| Category: Neuroscience | ||||||
| 07/31/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $29.90 | General |
| Category: NEUROSCIENCE | ||||||
| 07/17/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $14.16 | General |
| Category: NEUROSCIENCE | ||||||
| 07/16/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $19.90 | General |
| Category: Central Nervous System | ||||||
| 07/09/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $16.47 | General |
| Category: NEUROSCIENCE | ||||||
| 07/01/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $18.99 | General |
| Category: PSYCHIATRY | ||||||
| 06/25/2024 | BioXcel Therapeutics, Inc. | IGALMI (Drug) | Food and Beverage | In-kind items and services | $22.04 | General |
| Category: NEUROSCIENCE | ||||||
| 06/11/2024 | Lilly USA, LLC | AMYVID (Drug) | Food and Beverage | In-kind items and services | $19.37 | General |
| Category: Neuroscience | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $6,352 | 1 |
| A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | Eli Lilly and Company | $6,030 | 1 |
| A 24-MONTH, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, SAFETY, TOLERABILITY, BIOMARKER, AND PHARMACOKINETIC STUDY OF AZD3293 IN EARLY ALZHEIMERS DISEASE -THE AMARANTH STUDY | Eli Lilly and Company | $3,210 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $2,086 | 2 |
| ASSESSMENT OF SAFETY AND EFFICACY OF SUBCUTANEOUS REMTERNETUG IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $1,570 | 1 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $355.00 | 1 |
| 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease | Biogen, Inc. | $266.26 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 493 | 1,475 | $137,295 | $93,554 |
| 2022 | 8 | 658 | 1,851 | $170,990 | $120,142 |
| 2021 | 9 | 765 | 1,802 | $187,773 | $134,704 |
| 2020 | 14 | 1,209 | 2,642 | $275,479 | $171,924 |
Total Patients
3,125
Total Services
7,770
Medicare Billing
$520,324
Procedure Codes
37
All Medicare Procedures & Services
37 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 117 | 323 | $43,605 | $29,236 | 67.0% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2023 | 102 | 474 | $35,540 | $24,048 | 67.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 78 | 200 | $19,000 | $13,300 | 70.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 87 | 276 | $16,560 | $11,258 | 68.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 37 | 85 | $11,475 | $8,054 | 70.2% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 72 | 117 | $11,115 | $7,659 | 68.9% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 146 | 385 | $51,975 | $36,147 | 69.5% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2022 | 134 | 584 | $43,790 | $31,522 | 72.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 126 | 442 | $26,520 | $19,066 | 71.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 80 | 165 | $15,675 | $11,301 | 72.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 64 | 113 | $15,255 | $10,058 | 65.9% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 70 | 111 | $10,545 | $7,186 | 68.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 18 | 21 | $3,930 | $2,880 | 73.3% |
| 90846 | Family psychotherapy without patient, 50 minutes | Office | 2022 | 20 | 30 | $3,300 | $1,980 | 60.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 178 | 493 | $66,275 | $46,787 | 70.6% |
| 90833 | Psychotherapy performed with evaluation and management visit, 30 minutes | Office | 2021 | 124 | 422 | $31,640 | $22,599 | 71.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 120 | 320 | $30,175 | $21,535 | 71.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 89 | 178 | $23,990 | $18,329 | 76.4% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 104 | 167 | $15,775 | $11,203 | 71.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 42 | 58 | $10,958 | $8,028 | 73.3% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 65 | 97 | $5,820 | $4,459 | 76.6% |
| 90846 | Family psychotherapy, 50 minutes | Office | 2021 | 14 | 20 | $2,200 | $1,259 | 57.2% |
| 90785 | Interactive complexity | Office | 2021 | 29 | 47 | $940.00 | $504.84 | 53.7% |
| 90868 | Transcranial magnetic stimulation treatment (stimulates nerve cells in brain to improve symptoms of depression), per session | Office | 2020 | 11 | 255 | $86,168 | $37,936 | 44.0% |
| 90833 | Psychotherapy, 30 minutes | Office | 2020 | 235 | 655 | $49,125 | $34,548 | 70.3% |
About Dr. Jaron Winston, M.D
Dr. Jaron Winston, M.D is a Geriatric Psychiatry healthcare provider based in Austin, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/02/2005. The National Provider Identifier (NPI) number assigned to this provider is 1568463420.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jaron Winston, M.D has received a total of $28,821 in payments from pharmaceutical and medical device companies, with $2,169 received in 2024. These payments were reported across 389 transactions from 28 companies. The most common payment nature is "" ($19,870).
As a Medicare-enrolled provider, Winston has provided services to 3,125 Medicare beneficiaries, totaling 7,770 services with total Medicare billing of $520,324. Data is available for 4 years (2020–2023), covering 37 distinct procedure/service records.
Ad
Practice Information
- Specialty Geriatric Psychiatry
- Location Austin, TX
- Active Since 08/02/2005
- Last Updated 07/08/2007
- Taxonomy Code 2084P0805X
- Entity Type Individual
- NPI Number 1568463420
Products in Payments
- REXULTI (Drug) $949.44
- AUSTEDO (Drug) $939.02
- INGREZZA (Drug) $815.09
- VRAYLAR (Drug) $620.04
- CNP520 (Drug) $503.90
- NUPLAZID (Drug) $479.22
- SPRAVATO (Drug) $367.50
- TRINTELLIX (Drug) $202.86
- NUEDEXTA (Drug) $198.91
- Trintellix (Drug) $185.05
- NAMZARIC (Drug) $179.52
- Austedo XR (Drug) $151.52
- Fanapt (Drug) $147.73
- AMYVID (Drug) $144.83
- BELSOMRA (Drug) $112.49
- ADUHELM (Biological) $74.15
- HETLIOZ (Drug) $66.07
- Adlarity (Drug) $65.49
- SUNOSI (Drug) $62.01
- Auvelity (Drug) $55.26
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Geriatric Psychiatry Doctors in Austin
Dr. Scott Elkin, Do, DO
Geriatric Psychiatry — Payments: $3,890
Geriatric Psychiatry $3,890
Dr. Charlene Shero
Geriatric Psychiatry — Payments: $1,232
Geriatric Psychiatry $1,232
Dr. Prati Shah, M.d, M.D
Geriatric Psychiatry — Payments: $132.63
Geriatric Psychiatry $132.63
Erica Garcia-Pittman, Md, MD
Geriatric Psychiatry — Payments: $21.77
Geriatric Psychiatry $21.77
Dr. Andrey Tsyss, Do, DO
Geriatric Psychiatry
Geriatric Psychiatry